~~<i id='B0F1B57320'><strike id='B0F1B57320'><tt id='B0F1B57320'><pre id='B0F1B57320'></pre></tt></strike></i>~~

Home» Wikipedia» explore

explore

author：leisure time 2025-10-06 10:01:37 Page View：65

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Pfizer's RSV vaccine recommended for approval in Europe
Next article： Virginia high school admissions case could be legal follow

focus

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

UnitedHealth sued over use of algorithm in Medicare Advantage plans

PATRICKT.FALLON/AFPviaGettyImagesAclassactionlawsuitwasfiledTuesdayagainstUnitedHealthGroupandasubsi

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

UnitedHealth sued over use of algorithm in Medicare Advantage plans

PATRICKT.FALLON/AFPviaGettyImagesAclassactionlawsuitwasfiledTuesdayagainstUnitedHealthGroupandasubsi